869371-29-9 Usage
General Description
1-[1-(methylsulfonyl)-3-piperidinyl]methanamine (SALTDATA: HCl) is a chemical compound that consists of a piperidine ring with a methylsulfonyl group attached to it, and a methanamine group. It is commonly used as a pharmaceutical intermediate in the synthesis of various drugs. The hydrochloride salt form of this compound, with the addition of a hydrogen chloride molecule, is often used to improve the solubility and stability of the compound in pharmaceutical formulations. This chemical has the potential to exhibit various pharmacological effects and may be used in the treatment of certain medical conditions. It is important to handle and use this chemical with caution, following proper safety protocols and guidelines.
Check Digit Verification of cas no
The CAS Registry Mumber 869371-29-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,9,3,7 and 1 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 869371-29:
(8*8)+(7*6)+(6*9)+(5*3)+(4*7)+(3*1)+(2*2)+(1*9)=219
219 % 10 = 9
So 869371-29-9 is a valid CAS Registry Number.
869371-29-9Relevant articles and documents
Solid dispersions containing an apoptosis-inducing agent
-
Page/Page column 107, (2019/03/15)
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
